Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2199)	12/1/2000 6:30:03 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 52153

It is very interesting to see strategic assets (like drug discovery) loose their exclusivity, especially when what's left are soft skills like marketing and sales, for which there really is no long term competitive value other than scale. Horrifying, really, if you are big pharma...lucky there are now lots of targets and only a few BT labs with real money. Tells you how well managed (from a McKinsey point of view) is Pfizer. I don't know the sector, but why do you think no mention was made of Ilex Oncology...because it is not yet offering marketing and sales or maybe just not big enough? Anyway, have a good weekend everyone. A bad month, but no worries, BT leads the way in 2001...More Rituxan, More Enbrel, Bexxar, Zev, C225, Aranesp, Xolair, Lilly sepsis, Mabs galore, cancer vaccines, sleep and wakefulness drugs--and, drumroll, anti-C5 (data only). I'd add xcytrin if I knew how, when a patient with metastatic cancer in the lungs liver, brain and breast dies, they know the patient died other than from the brain metastises. --Wilder